Clinical and functional correlates of platelet cyclic GMP in essential hypertensives

American Journal of Hypertension

Volumn 22, Issue 6, 2009, Pages 674-679

  Sala, Carla ^a,b   Rescaldani, Marta ^a,b   Santin, Erika ^a,b   Bolla, Gianni ^a,b   Cuspidi, Cesare ^b  

^a Fondazione Policlinico di Milano   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; ADRENALIN; ALDOSTERONE; ATRIAL NATRIURETIC FACTOR; CYCLIC GMP; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ALDOSTERONE BLOOD LEVEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DEMOGRAPHY; DIASTOLIC BLOOD PRESSURE; ESSENTIAL HYPERTENSION; FEMALE; HEART RATE; HEART STROKE VOLUME; HUMAN; MAJOR CLINICAL STUDY; MALE; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; SEX DIFFERENCE; SMOKING; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE AGGREGATION;

ADULT; AGED; BIOLOGICAL MARKERS; BLOOD PLATELETS; BLOOD PRESSURE; CYCLIC GMP; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PROGNOSIS; RADIOIMMUNOASSAY; YOUNG ADULT;

EID: 67349249075     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1038/ajh.2009.60     Document Type: Article

References (33)

1. Ruggeri ZM. Platelets in atherothrombosis. Nat Med 2002; 8:1227-1234.
2. Mellion BT, Ignarro LJ, Ohlstein EH, Pontecorvo EG, Hyman AL, Kadowitz PJ. Evidence for the inhibitory role of guanosine 3′, 5′- monophosphate in ADP-induced human platelet aggregation in the presence of nitric oxide and related vasodilators. Blood 1981; 57:946-955.
3. Radomski MW, Palmer RM, Moncada S. An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci USA 1990; 87:5193-5197.
4. Lucas KA, Pitari GM, Kazerounian S, Ruiz-Stewart I, Park J, Schulz S, Chepenik K P, Waldman SA. Guanylyl cyclases and signaling by cyclic GMP. Pharmacol Rev 2000; 52:375-414.
5. Panza JA, Quyyumi AA, Brush JE, Epstein SE. Abnormal endothelium- dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990; 323:22-27.
6. Treasure CB, Klein JL, Vita JA, Manoukian SV, Renwick GH, Selwyn A P, Ganz P, Alexander RW. Hypertension and left ventricular hypertrophy are associated with impaired endothelium-mediated relaxation in human coronary resistance vessels. Circulation 1993; 87:86-93.
7. Halcox J P, Schenke WH, Zalos G, Mincemoyer R, Prasad A, Waclawiw MA, Nour KR, Quyyumi AA. Prognostic value of coronary vascular endothelial dysfunction. Circulation 2002; 106:653-658.
8. Zhou Q, Hellermann GR, Solomonson L P. Nitric oxide release from resting human platelets. Thromb Res 1995; 77:87-96.
9. Camilletti A, Moretti N, Giacchetti G, Faloia E, Martarelli D, Mantero F, Mazzanti L. Decreased nitric oxide levels and increased calcium content in platelets of hypertensive patients. Am J Hypertens 2001; 14:382-386.
10. Cadwgan TM, Benjamin N. Evidence for altered platelet nitric oxide synthesis in essential hypertension. J Hypertens 1993; 11:417-420.
11. Hoffmann G, Göbel BO, Harbrecht U, Vetter H, Düsing R. Platelet cAMP and cGMP in essential hypertension. Am J Hypertens 1992; 5:847-850.
12. Ramchandra R, Barrett CJ, Malpas SC. Nitric oxide and sympathetic nerve activity in the control of blood pressure. Clin Exp Pharmacol Physiol 2005; 32:440-446.
13. Watanabe H, Kakihana M, Ohtsuka S, Enomoto T, Yasui K, Sugishita Y. Platelet cyclic GMP. A potentially useful indicator to evaluate the effects of nitroglycerin and nitrate tolerance. Circulation 1993; 88:29-36.
14. Sagnella GA, Markandu ND, Buckley MG, Singer DR, MacGregor GA. Atrial natriuretic peptide-cyclic GMP relationships in normal humans: effects of dietary sodium intake. Clin Sci 1993; 85:13-17.
15. Arnold W P, Mittal CK, Katsuki S, Murad F. Nitric oxide activates guanylate cyclase and increases guanosine 3′:5′-cyclic monophosphate levels in various tissue preparations. Proc Natl Acad Sci USA 1977; 74:3203-3207.
16. Blaise V, Wolf J P, Regnard J, Berthelay S. Characterization of human platelet receptors for atrial natriuretic peptide: evidence for clearance receptors. Cell Mol Biol 1996; 42:1173-1179.
17. Sala C, Ambrosi B, Morganti A. Blunted vascular and renal effects of exogenous atrial natriuretic peptide in patients with Cushing's disease. J Clin Endocrinol Metab 2001; 86:1957-1961.
18. Ikeda H, Takajo Y, Murohara T, Ichiki K, Adachi H, Haramaki N, Katoh A, Imaizumi T. Platelet-derived nitric oxide and coronary risk factors. Hypertension 2000; 35:904-907.
19. Taddei S, Virdis A, Mattei P, Ghiadoni L, Sudano I, Salvetti A. Defective L-arginine-nitric oxide pathway in offspring of essential hypertensive patients. Circulation 1996; 94:1298-1303.
20. Adams MR, Forsyth CJ, Jessup W, Robinson J, Celermajer DS. Oral L-arginine inhibits platelet aggregation but does not enhance endothelium-dependent dilation in healthy young men. J Am Coll Cardiol 1995; 26:1054-1061.
21. Mehta JL, Chen LY. Reversal by high-density lipoprotein of the effect of oxidized low-density lipoprotein on nitric oxide synthase protein expression in human platelets. J Lab Clin Med 1996; 127:287-295.
22. Naqvi TZ, Shah PK, Ivey PA, Molloy MD, Thomas AM, Panicker S, Ahmed A, Cercek B, Kaul S. Evidence that high-density lipoprotein cholesterol is an independent predictor of acute platelet-dependent thrombus formation. Am J Cardiol 1999; 84:1011-1017.
23. Hanke CJ, O'Brien T, Pritchard KA, Campbell WB. Inhibition of adrenal cell aldosterone synthesis by endogenous nitric oxide release. Hypertension 2000; 35:324-328.
24. Goodfriend TL, Egan B, Stepniakowski K, Ball DL. Relationships among plasma aldosterone, high-density lipoprotein cholesterol, and insulin in humans. Hypertension 1995; 25:30-36.
25. Moraes LA, Paul-Clark MJ, Rickman A, Flower RJ, Goulding NJ, Perretti M. Ligand-specific glucocorticoid receptor activation in human platelets. Blood 2005; 106:4167-4175.
26. Reiter CD, Wang X, Tanus-Santos JE, Hogg N, Cannon RO, Schechter AN, Gladwin MT. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med 2002; 8:1383-1389.
27. Brewer HB. Increasing HDL cholesterol levels. N Engl J Med 2004; 350:1491-1494.
28. Eichinger S, Pecheniuk NM, Hron G, Deguchi H, Schemper M, Kyrle PA, Griffin JH. High-density lipoprotein and the risk of recurrent venous thromboembolism. Circulation 2007; 115:1609-1614.
29. Gordon T, Castelli W P, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977; 62:707-714.
30. Goto S, Handa S, Takahashi E, Abe S, Handa M, Ikeda Y. Synergistic effect of epinephrine and shearing on platelet activation. Thromb Res 1996; 84:351-359.
31. Freedman JE, Ting B, Hankin B, Loscalzo J, Keaney JF, Vita JA. Impaired platelet production of nitric oxide predicts presence of acute coronary syndromes. Circulation 1998; 98:1481-1486.
32. Bilodeau ML, Hamm HE. Regulation of protease-activated receptor (PAR) 1 and PAR4 signaling in human platelets by compartmentalized cyclic nucleotide actions. J Pharmacol Exp Ther 2007; 322:778-788.
33. Li Z, Xi X, Gu M, Feil R, Ye RD, Eigenthaler M, Hofmann F, Du X. A stimulatory role for cGMP-dependent protein kinase in platelet activation. Cell 2003; 112:77-86.